Zacks Research Forecasts Higher Earnings for Globus Medical

Globus Medical, Inc. (NYSE:GMED - Free Report) - Zacks Research increased their Q1 2026 earnings per share (EPS) estimates for Globus Medical in a research report issued to clients and investors on Monday, November 4th. Zacks Research analyst R. Department now expects that the medical device company will earn $0.85 per share for the quarter, up from their previous forecast of $0.84. The consensus estimate for Globus Medical's current full-year earnings is $2.84 per share. Zacks Research also issued estimates for Globus Medical's Q3 2026 earnings at $1.03 EPS.

Several other research analysts also recently issued reports on GMED. Bank of America upped their target price on shares of Globus Medical from $55.00 to $80.00 and gave the stock an "underperform" rating in a research note on Wednesday. Royal Bank of Canada boosted their price objective on shares of Globus Medical from $80.00 to $92.00 and gave the stock an "outperform" rating in a report on Wednesday. Piper Sandler increased their target price on Globus Medical from $80.00 to $100.00 and gave the company an "overweight" rating in a research note on Wednesday. Stifel Nicolaus boosted their price target on Globus Medical from $80.00 to $92.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Canaccord Genuity Group increased their price objective on Globus Medical from $79.00 to $85.00 and gave the company a "buy" rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Globus Medical presently has a consensus rating of "Moderate Buy" and a consensus target price of $87.09.

Globus Medical Price Performance

Globus Medical stock traded up $7.12 during mid-day trading on Wednesday, reaching $82.70. The stock had a trading volume of 3,865,942 shares, compared to its average volume of 998,129. Globus Medical has a one year low of $43.38 and a one year high of $84.87. The company has a 50-day moving average price of $71.92 and a two-hundred day moving average price of $68.16. The company has a market capitalization of $11.20 billion, a price-to-earnings ratio of 275.67, a PEG ratio of 2.07 and a beta of 1.17.

Globus Medical (NYSE:GMED - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.18. Globus Medical had a return on equity of 8.70% and a net margin of 1.82%. The company had revenue of $625.71 million during the quarter, compared to analyst estimates of $604.69 million. During the same quarter last year, the company earned $0.57 EPS. The firm's revenue for the quarter was up 63.1% on a year-over-year basis.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. V Square Quantitative Management LLC bought a new position in Globus Medical in the 3rd quarter worth $27,000. Ashton Thomas Private Wealth LLC bought a new position in shares of Globus Medical in the second quarter worth about $33,000. Farther Finance Advisors LLC grew its position in shares of Globus Medical by 230.5% during the third quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company's stock worth $39,000 after purchasing an additional 385 shares in the last quarter. GAMMA Investing LLC raised its stake in Globus Medical by 254.5% during the 2nd quarter. GAMMA Investing LLC now owns 631 shares of the medical device company's stock valued at $43,000 after purchasing an additional 453 shares during the period. Finally, International Assets Investment Management LLC bought a new stake in Globus Medical during the 2nd quarter valued at approximately $52,000. 95.16% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 30,000 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $75.04, for a total value of $2,251,200.00. Following the transaction, the director now owns 536,275 shares in the company, valued at $40,242,076. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Ann D. Rhoads sold 15,000 shares of Globus Medical stock in a transaction on Friday, September 13th. The stock was sold at an average price of $70.36, for a total transaction of $1,055,400.00. Following the transaction, the director now directly owns 42,884 shares in the company, valued at approximately $3,017,318.24. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David D. Davidar sold 30,000 shares of the business's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $75.04, for a total value of $2,251,200.00. Following the sale, the director now directly owns 536,275 shares of the company's stock, valued at $40,242,076. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 18.54% of the company's stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.